Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-21
    E.g., 2018-02-21

Articles

19177 items
1:04 PM, Dec 22, 2017  |  BioCentury | Finance

Flying high

Flagship Pioneering has expanded its LP base with its sixth fund to meet its goal of launching six to eight newcos per year out of its VentureLabs unit. Flagship Pioneering Fund VI L.P. closed on...
12:45 PM, Dec 22, 2017  |  BioCentury | Product Development

Beyond PD-L1 assays

Data from Genentech Inc.’s Phase III IMpower150 trial of Tecentriq atezolizumab in first-line non-small cell lung cancer provides the company with its first hard data showing what work lies ahead before it will be ready...
10:32 AM, Dec 22, 2017  |  BioCentury | Finance

Orchard’s supply

Promising early data for a rare disease lentiviral gene therapy from Orchard Therapeutics Ltd. helped the Orphan disease company raise a $110 million series B round that it thinks will be enough to carry its...
10:28 AM, Dec 22, 2017  |  BioCentury | Finance

Modulating mechanism

Aptinyx Inc. parlayed preclinical proof-of-concept data for NYX-2925 into an untranched $70 million series B round that should give the neurology company runway through YE19, when it expects to have data from Phase II trials...
6:15 PM, Dec 15, 2017  |  BioCentury | Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
4:52 PM, Dec 15, 2017  |  BioCentury | Regulation

Growth medium

FDA’s regenerative medicines framework could level the global regulatory playing field for products like cell and gene therapies. It describes approaches to implementing expedited development and review pathways that make them comparable, and in some...
1:58 PM, Dec 15, 2017  |  BioCentury | Emerging Company Profile

CD38 hat trick

Tusk Therapeutics Ltd. thinks its anti-CD38 mAb could be best in class for solid tumors because it not only kills cancer cells and inhibits immunosuppressive cells, as its competitors do, but it also directly activates...
1:57 PM, Dec 15, 2017  |  BioCentury | Product Development

Patient-powered precision

The Harvard Business School’s Kraft Precision Medicine Accelerator is tackling a series of initiatives that will position patients to help drive improvements in both clinical care and clinical research. The accelerator was founded in 2015 with...
1:28 PM, Dec 15, 2017  |  BioCentury | Finance

Kyndred spirits

Partners Kyn Therapeutics Inc. and Arrys Therapeutics Inc. share an investor syndicate and a focus on cancer therapies targeting metabolic pathways in immune cells. However, the companies are keeping their assets separate to keep the...
10:30 AM, Dec 15, 2017  |  BioCentury | Finance

LSP’s big cost-saving fund

Strong early returns from LSP’s first fund explicitly targeting companies that generate savings for healthcare systems had LPs clamoring to get into a second fund that will follow the same strategy. On Dec. 11, LSP...

Pages